As indicated, effective use of protein drugs can be compromised by their instability in the body, rapid rates of clearance, premature uptake by tissues and immunogenicity or antigenicity.

Coherus Showcases Early-Stage Study Results for its Novel IL-27-Specific Antibody, Casdozokitug, at ESMO's 2023 Immuno-Oncology Meeting.

PCSK9 inhibitors can significantly reduce LDL-C levels, and the development of related drugs is of great importance for the treatment of cardiovascular diseases.

Qilu Pharma Reports Data on Phase 2 Trial of Iparomlimab in Treating Progressive Solid Cancers, Reveals 45.8% Objective Response Rate at ESMO Asia Conference.

Pharmacometric models describe the current understanding of the drug/therapy and simulations help predict next steps for testing the drug in animals and humans.

First patient with swiftly advancing ANCA-Related Vasculitis and kidney inflammation enrolled and treated in Phase II study of new drug Lixudebart (ALE.F02) by Alentis Therapeutics.

p53 inhibitors are pharmaceutical compounds that inhibit the tumor-suppressing p53 protein, offering potential therapeutic strategies for various types of cancers.

GT Biopharma, Inc., a clinical-stage immuno-oncology company, is committed to developing innovative therapies using its proprietary TriKE® NK cell technology. The firm recently announced it filed an IND application with the US FDA for its new drug, GTB-3650.

The market is expected to benefit from constant growth in the genomics and genetic modification markets as progress in genetic instruments simplifies oligonucleotide synthesis.

Everest Medicines, a biopharma company, announced that China's National Medical Products Administration has accepted their IND application for the drug candidate zetomipzomib in China.

Neuraminidase inhibitors are drugs that target the neuraminidase enzyme, crucial for combating influenza virus infections.

FDA Grants Approval for CARsgen's Experimental Treatment CT071 for Use in Cases of Recurrent Multiple Myeloma and Primary Plasma Cell Leukemia After Prior Therapies Fail.